4,532 Shares in Astrazeneca Plc $AZN Acquired by Keenan LLC

Keenan LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,532 shares of the company’s stock, valued at approximately $795,000. Astrazeneca comprises approximately 0.7% of Keenan LLC’s holdings, making the stock its 24th largest holding.

Several other large investors also recently added to or reduced their stakes in AZN. Arrowstreet Capital Limited Partnership raised its holdings in shares of Astrazeneca by 552.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after acquiring an additional 4,697,895 shares during the period. Bank of Montreal Can boosted its position in shares of Astrazeneca by 344.6% during the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after acquiring an additional 2,695,793 shares during the last quarter. Citigroup Inc. grew its holdings in shares of Astrazeneca by 65.3% in the fourth quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock valued at $1,080,160,000 after purchasing an additional 2,431,890 shares during the period. Holocene Advisors LP grew its holdings in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Astrazeneca by 11,190.9% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after purchasing an additional 1,790,874 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Down 0.0%

Shares of AZN opened at $174.87 on Friday. The company’s 50-day moving average price is $186.62 and its 200 day moving average price is $186.27. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market cap of $271.20 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, sell-side analysts forecast that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on AZN. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.